Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) EBT Margin (2020 - 2025)

Fennec Pharmaceuticals' EBT Margin history spans 6 years, with the latest figure at 15.48% for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 3442.0% year-over-year to 15.48%, compared with a TTM value of 6.29% through Dec 2025, down 667.0%, and an annual FY2025 reading of 21.58%, down 4694.0% over the prior year.
  • EBT Margin for Q4 2025 was 15.48% at Fennec Pharmaceuticals, up from 5.0% in the prior quarter.
  • The five-year high for EBT Margin was 43522.22% in Q2 2021, with the low at 355.34% in Q1 2023.
  • Average EBT Margin over 5 years is 4055.31%, with a median of 9.15% recorded in 2025.
  • Year-over-year, EBT Margin crashed -3465029bps in 2022 and then skyrocketed 40619bps in 2024.
  • Tracing FENC's EBT Margin over 5 years: stood at 7663.64% in 2021, then crashed by -90bps to 754.38% in 2022, then tumbled by -104bps to 26.89% in 2023, then grew by 30bps to 18.94% in 2024, then surged by 182bps to 15.48% in 2025.
  • Per Business Quant, the three most recent readings for FENC's EBT Margin are 15.48% (Q4 2025), 5.0% (Q3 2025), and 32.69% (Q2 2025).